Here is an article based on the Business Wire announcement regarding Adocia’s semi-annual liquidity contract report:
Adocia Releases Semi-Annual Report on Liquidity Contract with Kepler Capital Markets
Lyon, France – Adocia, a clinical-stage biopharmaceutical company dedicated to the development of innovative rapid-acting insulins and other bio-better products, has announced the semi-annual assessment of its liquidity contract with Kepler Capital Markets. This report details the performance and activities undertaken under the liquidity agreement over the past six months.
The liquidity contract, established to foster an orderly and liquid market for Adocia’s shares, is managed by Kepler Capital Markets, a well-respected financial institution. This arrangement is a common practice for publicly traded companies and aims to ensure a stable trading environment for investors.
According to the publicly released information, the semi-annual review confirms the execution of the liquidity contract within its defined framework. The activities undertaken by Kepler Capital Markets, as stipulated by the agreement, are designed to contribute positively to the trading of Adocia’s securities without artificially influencing the market. This includes market-making activities, which can help to narrow bid-ask spreads and improve the overall liquidity of the stock.
Adocia has consistently demonstrated its commitment to transparency and robust corporate governance. The regular reporting on the liquidity contract underscores this dedication, providing stakeholders with timely updates on the measures in place to support the market for its shares.
The company continues to focus on its primary mission: advancing its pipeline of innovative therapeutic solutions, particularly in the area of diabetes management with its rapid-acting insulins like BioChaperone® Lispro. Updates on its clinical trials and strategic development will remain the core focus of investor interest.
This semi-annual report on the liquidity contract serves as an important piece of information for investors and the broader financial community, reinforcing Adocia’s commitment to maintaining a well-functioning market for its stock while pursuing its ambitious development objectives.
About Adocia
Adocia is a clinical-stage biopharmaceutical company that designs and develops innovative drug combinations. Its most advanced product, BioChaperone® Lispro, combines a rapid-acting insulin with a novel technology to potentially improve insulin delivery and glycemic control for people with diabetes. Adocia’s pipeline also includes other promising candidates for diabetes and other metabolic diseases. The company is listed on the regulated market of Euronext Paris.
ADOCIA annonce le bilan semestriel du contrat de liquidité conclu avec Kepler Capital Markets
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
Business Wire French Language News published ‘ADOCIA annonce le bilan semestriel du contrat de liquidité conclu avec Kepler Capital Markets’ at 2025-07-16 16:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.